Phase 1 clinical trial underway for a vaccine candidate againstinfluenza A “Universal” BPL-1357. This worldwide flu causes 3 to 5 million serious illnesses and up to 650,000 deaths every year. In one study, the vaccine was tested on mice and ferrets that survived lethal doses of 6 different flu strains. Also included are subtypes that do not belong to the 4 non-infectious, inactivated avian influenza virus strains that make up the experimental vaccine.

So the study will do the random administration of 2 doses to up to 100 healthy adults between the ages of 18 and 55. 28 days away. It involves administering a intramuscular vaccine active and a intranasal placebo, an intranasal vaccine and an intramuscular placebo or 2 placebos. Scientists created this virus-wide vaccine candidate to elicit a full mucosal and cellular immune response similar to a natural infection.

Samples of nasal mucosa and blood taken monthly for 7 months will allow to determine the role ofmucosal immunity. Evaluate its presence in protection against infection and whether induction of both cellular and mucosal immunity enhances protection.

Vaccines that can provide lasting protection against a wide range of seasonal flu viruses and viruses with pandemic potential would be invaluable to public health.

Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID)

Source: Lega Nerd

Previous articlePS5 from Sony rises in price, but loses weight in the new model
Next article10 tech news to start the day (08/30)
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.


Please enter your comment!
Please enter your name here